2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
78 citations
,
March 2004 in “Annals of Oncology” The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
April 2023 in “Dermatology practical & conceptual” Lenalidomide helps hair follicle stem cells turn into melanocytes, which may improve repigmentation in vitiligo.
39 citations
,
May 2004 in “Clinics in Dermatology” The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
23 citations
,
December 2004 in “Seminars in oncology” Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
11 citations
,
January 2022 in “Journal of Cancer” Low intensity ultrasound may reduce side effects of chemotherapy drugs like paclitaxel.
153 citations
,
January 2001 in “Science” Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
9 citations
,
February 2012 in “Cancer Chemotherapy and Pharmacology” The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
May 2015 in “Cancer research” After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.
13 citations
,
August 2018 in “Life sciences” Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
October 2006 in “Clinical Cancer Research” Antioxidants can block the cancer-fighting effects of doxorubicin.
1 citations
,
July 2016 in “Dermatologic surgery” 1 citations
,
January 1998 in “International journal of cancer” Rubbing vitamin D3 on skin can help prevent hair loss from chemotherapy and slow breast tumor growth in mice.
1 citations
,
November 2023 in “BMC chemistry” Tadalafil and Finasteride may help treat aggressive melanoma.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
1 citations
,
October 2014 in “Annals of oncology” Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
June 2018 in “Reactions Weekly” A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.
2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
September 1999 in “Molecular Carcinogenesis” Increased ODC expression makes normally tumor-resistant mice more prone to tumor development.
1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
25 citations
,
April 2010 in “Clinical and Experimental Dermatology” Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.
January 2021 in “Annals of translational medicine” YH0618 helped reduce skin and nail problems and fatigue in chemotherapy patients.